Thématique :
- Cancers autres (hors CCR et CHC)
- Pancréas
Originalité :
Solidité :
A confirmer
Doit faire évoluer notre pratique :
Dans certains cas
Nom du veilleur :
Professeur Sylvain MANFREDI
Coup de coeur :
Digestive and Liver Disease
  2019 Jan;51(1):28-37.  
  doi: 10.1016/j.dld.2018.09.007.  
  Meta-Analysis Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis  
  Archibugi L, Arcidiacono PG, Capurso G  



Previous studies investigating the association between statin use and pancreatic cancer (PDAC) risk for a possible chemopreventive effect gathered heterogeneous results.


To conduct a systematic review and meta-analysis to clarify this association.


Comprehensive literature search of articles published up to February 2018, including case-control (CC),cohort studies (C), randomized controlled trials (RCTs) assessing association between statin use and PDAC risk. Studies had to report odds ratio (OR)/relative risk (RR), estimates with 95% confidence interval (CI), or provide data for their calculation. Pooled ORs with 95%CIs were calculated using random effects model, publication bias through Begg and Mazumdar test and heterogeneity by I2 value.


27 studies(13 CC, 9C, 5 RCTs) for a total population of 11,975 PDAC/3,433,175 controls contributed to the analysis. The overall pooled result demonstrated a reduced PDAC risk among statin users (OR 0.70; 95% CI 0.60-0.82; p < 0.0001), compared to non-users. Sensitivity analyses suggested the risk reduction to be more important in CC studies, studies conducted in Asia and Europe, in males and atorvastatin users. No publication bias found.


The present meta-analysis suggests that statin use is associated with an overall PDAC risk reduction of 30%. Further studies are needed to clarify the association.

Question posée
Méta-analyse de 27 études visant à étudier l’effet de chimio-prévention des statines dans le cancer du pancréas.
Question posée
La prise de statine réduit le risque de cancer du pancréas de 30%.